Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases

Hiroaki Shimokawa

研究成果: Review article査読

251 被引用数 (Scopus)

抄録

Rho-kinase has been identified as one of the effectors of the small GTP-binding protein Rho. Accumulating evidence has demonstrated that the Rho/Rho-kinase-mediated pathway plays an important role in various cellular functions, not only in vascular smooth muscle contraction but also in actin cytoskeleton organization, cell adhesion and motility, cytokinesis, and gene expressions, all of which may be involved in the pathogenesis of arteriosclerosis/atherosclerosis. Indeed, animal experiments have demonstrated that Rho-kinase inhibitors effectively suppress coronary artery spasm and that long-term inhibition of Rho-kinase inhibits the development of coronary arteriosclerotic lesions and even causes regression of coronary vascular lesions in vivo. Recent clinical studies also have demonstrated the inhibitory effect of a Rho-kinase inhibitor on coronary artery spasm in patients with vasospastic angina and on exercise-induced myocardial ischemia in patients with stable effort angina with adequate safety. It is possible that Rho-kinase is also involved in the pathogenesis of other forms of cardiovascular diseases. Thus, Rho-kinase could be regarded as a novel therapeutic target in treatment of cardiovascular diseases.

本文言語English
ページ(範囲)319-327
ページ数9
ジャーナルJournal of cardiovascular pharmacology
39
3
DOI
出版ステータスPublished - 2002

ASJC Scopus subject areas

  • 薬理学
  • 循環器および心血管医学

フィンガープリント

「Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル